After Albireo (ALBO) announced an agreement to be acquired by Ipsen (IPSEY) at a price of $42.00 per share in cash for an initial estimated aggregate consideration of $952M plus one contingent value right, or CVR, worth $10.00 per CVR payable upon the FDA approval of Bylvay in the Biliary Atresia indication, Piper Sandler analyst Yasmeen Rahimi said this is "good news" for Mirum Pharmaceuticals (MIRM), a direct competitor in the pediatric liver disease space. The deal highlights the interest around the ileal bile acid transport inhibitor, or IBATi, mechanism and "bodes well" for Mirum, which has an already validated track record of successful IBATis, according to Rahimi. The analyst, who expects to see share gains for Mirum and "further interest from pharma in its valuable pipeline," keeps an Overweight rating and $77 price target on Mirum shares.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MIRM:
- Mirum Pharmaceuticals sees FY22 Livmarli net product sales $74M
- Mirum Pharmaceuticals sees FY22 revenue $74M, consensus $72.85M
- Mirum Pharmaceuticals announces EC marketing authorization for Livmarli
- Mirum Pharmaceuticals to discontinue OHANA study of volixibat in ICP
- Mirum Pharmaceuticals price target raised to $69 from $68 at H.C. Wainwright